Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights

Biomarkers in Oncology | Access & Reimbursment | US | NSCLC, Bladder Cancer, and Gastric / GEJ Adenocarcinoma | 2021

Login to access report north_east
Contact sales account_box

Biomarker-driven prescribing is paramount in key oncology indications. The use of biomarkers is entrenched in indications such as non-small-cell lung cancer (NSCLC) and bladder cancer and is playing an increasingly important role in indications such as gastric and gastroesophageal junction (GEJ) adenocarcinoma. Although biomarker-associated therapies offer the advantage of selecting the patients most likely to respond to treatment, these therapies are premium-priced and often subject to payer restrictions and cost-containment strategies.

QUESTIONS ANSWERED

· What factors largely influence payers’ reimbursement decisions for biomarker-driven therapies in NSCLC, bladder cancer, and gastric and GEJ adenocarcinoma? What restrictions do they impose?

· Do access and reimbursement challenges differ by indication, and how well established are biomarkers in each indication?

· What impact do reimbursement and cost have in oncologists’ decisions to prescribe biomarker-driven therapies?

· What are payer opinions of emerging agents, and how will oncologists’ prescribing patterns change with the launch of new therapies?

· What factors influence reimbursement and access of companion biomarker tests?

GEOGRAPHY: United States.

PRIMARY RESEARCH: Survey of 100 U.S. medical oncologists and 30 U.S. managed care organization (MCO) pharmacy directors and medical directors (PDs/MDs).

KEY DRUGS COVERED:

Tagrisso, Tarceva, Gilotrif, Iressa, Vizimpro, Rybrevant, Lumakras, Tabrecta, Tepmetko, Retevmo, Gavreto, Keytruda, Tecentriq, Balversa, Opdivo, and Enhertu

CONTENT HIGHLIGHTS:

  • Reimbursement and contracting
  • Access and prescribing
  • Opportunities and challenges for emerging therapies
  • Disease-specific special topic
Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Scleroderma (Systemic Sclerosis) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Scleroderma (Systemic Sclerosis) (US)
Scleroderma (systemic sclerosis) (SSc) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that can manifest as Raynaud’s phenomenon…
north_east
Report
Hypertrophic Cardiomyopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hypertrophic Cardiomyopathy (US)
HCM is a genetic heart condition characterized by thickened myocardium and left ventricular hypertrophy, often linked to sarcomere mutations. While some patients remain asymptomatic, common…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Geographic Focus: China – Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – China In-Depth (China)
The NHL therapy market in China is poised for significant growth over the next decade, driven by the introduction of novel therapies and the continued uptake and label expansion of premium-priced…
north_east
Report
Bladder Cancer and Upper Tract Urothelial Carcinoma – Landscape & Forecast – Disease Landscape & Forecast (G7)
The treatment landscape for bladder cancer and upper tract urothelial carcinoma (UTUC) continues to evolve with the expanding role of immune checkpoint inhibitors and novel targeted therapies. The…
north_east
Report
Breast Cancer – Geographic Focus: China – China In-Depth – Breast Cancer
The breast cancer therapy market in mainland China is one of the most dynamic in the oncology sector. Several new and emerging therapies are expected to gain approval for specific subpopulations,…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east